News
We are pleased to announce that the Office of Sponsored Projects Administration (OSPA) has a new staff member, John Craddock. John joins the staff under the auspices of the Vice President for Research with the goal of proactively streamlining compliance for UK investigators seeking funding that may be regulated by export control laws. John has worked as a Principal Investigator at the Center for Applied Energy Research on several export controlled projects where he developed protocols to remain in compliance with U.S. export control laws.
The Office of Sponsored Projects Administration, the Proposal Development Office, the Office of Research Integrity–IRB, the Survey Research Center and the COM Sponsored Research Administrative Services offices will be closed Monday, December 26, 2016 through Monday, January 2, 2017 and will reopen on Tuesday, January
The Final Research Performance Progress Report (F-RPPR) will replace the Final Progress Report (FPR) for grants closeout, effective January 1, 2017. The F-RPPR will be available for use in eRA Commons on January 1, 2017.
NOTE: For small businesses, the new F-RPPR will be in effect at least 2 months later, due to the unique final reporting requirements that they face under the SBIR/STTR policy directive.
For faculty members who are working with industry sponsors (non-clinical trial) for their research projects, please contact your COM Sponsored Research Administrative Services (SRAS) Grants Proposal Specialist (GPS), who can assist you during the time that you are negotiating your budget figures with the sponsor. Your GPS can assist with:
Answering your questions about what costs are allowable on industry-sponsored agreements.
John Gensel, an assistant professor in the physiology department and the Spinal Cord and Brain Injury Research Center, and two members of his lab team—Bei Zhang and Taylor Otto—are featured in this podcast.
Taylor Otto, an undergraduate lab assistant in Gensel’s lab, described UK as being the full package. “We have it all here. It’s a good program to be able to come into, not really knowing what you want to exactly do in the science field, but being able to figure it out at the same time,” said Otto.
In the spring of 2016, the University of Kentucky hired Dr. Robert DiPaola as the new dean for the UK College of Medicine. He had previously been the director of the Rutgers Cancer Institute of New Jersey and vice chancellor for cancer programs at the Rutgers Biomedical and Health Sciences Center.
In an effort to be fair to all, NIH has been consistently applying its standards for application compliance. This consistency means that some applications recently have been rejected due to non-compliance. Issues that can lead NIH to reject an application include but are no limited to:
University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000s. Commonly known as Herceptin, this drug became a standard of care for patients with HER2-positive breast cancer.
Though he retired from practice last year, Romond continues to work part-time with the research team at Markey, this time pushing toward a cure for a different, more deadly, type of breast cancer.
When we think of research, our minds may possibly conjure up an image of a scientist in a white coat, hunched over a lab table, pouring chemicals into beakers. But research takes a multitude of forms, and flourishes in many different fields. From clinical trials for new cancer medication, to composing and recording an album of original music, and even to studying and refining the most effective ways to cure a country ham. Research often leads us toward answering questions we didn’t even think to ask.
The University of Kentucky Center for Clinical and Translational Science (CCTS) announced today that it received a four-year, $19.8 million Clinical and Translational Science Award (CTSA) from the National Center for Advancing Clinical and Translational Sciences at the National Institutes of Health. CTSA grants support innovative solutions to improve the efficiency, quality, and impact of translating scientific discoveries into interventions or
Nika Larian, a PhD student in Lisa Cassis's lab at the UK Superfund Research Center, is studying the aryl hydrocarbon receptor, or AHR, a transcription factor with roles in drug metabolism and detoxification. She explains that if you knock out AHR in the fat tissue of mice, you can prevent the development of polychlorinated biphenyl (PCB)-induced diabetes. PCBs are toxins that are present in the environment and have been linked to type 2 diabetes.
Easy access to academic journals on your smartphone
Below is a list of upcoming workshops provided by the Proposal Development Office:
October 25, 2016
Your NIH Biosketch - Make it an Asset